DR. MARC SIEGEL: More bad news about our kids' health. Is Ozempic the solution?
Please note: this is not connected to the kind of diabetes (type 1) that is autoimmune or tied to genetics and the most common form diagnosed it childhood, but the kind (type 2) where you don't make enough insulin to drive the glucose you have into the cells and where insulin resistance builds up. And it doesn't take actual type 2 diabetes to do that. Pre-diabetes is well on the road to actual diabetes, though it can often still be reversed by lifestyle changes. The inflammation and excess glucose associated with pre-diabetes can also damage kidneys, coronary arteries, retinas, and nerves, whether a child goes on to develop full type 2 diabetes or not.
Considering that between 21 and 40% of obese patients have pre-diabetes, and considering that the GLP1 agonist drugs including Ozempic and Wegovy are highly effective at not just glucose control but also weight loss, and adding to that they appear to have cardioprotective effects and are also seemingly good for the brain, it is no surprise that there is a huge clamor for them all across America. So shouldn't all of our children with a weight or sugar problem be on them?
The answer is a resounding no.
Not only are there concerns about gastrointestinal side effects and intolerance, but optical side effects (headaches, macular degeneration, and even loss of vision have been reported) need to be further studied along with thyroid cancer concerns. Currently, there is no data on long-term side effects and a child who, once committed to them, could be on these drugs for life.
It is easy to see that the benefits outweigh the risks much more for adults than for most children.
Also, at a time when there is an epidemic of social media and excess screen-time addiction, where our children's diets are filled with ultra-processed high-sugar foods, when too many children are not exercising, I feel it would be a big mistake to rush to these semaglutide drugs as a quick fix to the problem.
Don't get me wrong, I much prefer the drugs to the long-term side effects of obesity, which include all the diseases and more mentioned above. If I knew for sure that a child was in a group where they were destined for diabetes or heart disease because of their weight and I could do something about it, of course I would, but most of the time there are lifestyle changes to promote first. Clearly, we have a long way to go to improve our kids' diets, but now is the time to start.
For those children with persistent obesity and/or prediabetes, a nutritionist along with an endocrinologist should be involved, but for most, it should be a very runway before the Ozempic or Wegovy plane is launched, at least for now.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus
SCOTTSDALE, ARIZONA / / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated. Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or "normal aging," while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility. Widespread, Under-Recognized Health Threat CVI, also known as chronic venous disease or venous reflux disease, impacts twice (2x) as many Americans as coronary heart disease, three times (3x) peripheral arterial disease, and 30 times (30x) the number of Americans who have a heart attack each year. According to CDC, up to 900,000 Americans are affected by venous thromboembolism annually, and 60,000 to 100,000 people die each year. Millions suffer daily challenges - standing, sitting, flying - due to blood pooling in the legs, worsened by inactivity or pressure. Traditional treatments - leg elevation, compression stockings or surgical procedures - are often cumbersome, uncomfortable, underutilized, and may be expensive with added health risks. Life-Changing Solution: Vasculera® Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and: Calms inflammation and oxidative stress Strengthens weakened vein walls Improves overall venous function Counters localized CVI blood acidosis Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo. Expert Physician Perspectives "CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity," said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. "Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition." Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, "CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications." Robust Clinical Backing Over 60 published peer-reviewed clinical studies confirm diosmin's effectiveness in reducing leg pain, swelling, and skin deterioration associated with CVI. Vascular medicine experts recommend Vasculera's ultra-micronized diosmin as the only U.S. product for venous ulcers and CVI symptoms, both as standalone and adjunctive therapy in national treatment guidelines. Public Health Call to Action With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to: Proactively screen all at-risk patients for CVI Integrate proven prescription metabolic therapies like Vasculera with CVI standards of care For prescribing information, visit About Primus Pharmaceuticals Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit Contact Information Randy Keating Public Relations Managerrkeating@ SOURCE: Primus Pharmaceuticals View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
Yahoo
7 hours ago
- Yahoo
TikTokers are obsessed with ‘fibermaxxing'. Here's what the experts say
Break out the chia pudding! The social media trend known as 'fibermaxxing' wants you to add more fiber to your daily diet. TikTok users tout the health benefits of including simple foods packed with the carbohydrate, including the relieving effects in the bathroom. Some TikTokers point to the recent rise in rates of colon cancer in young people, and note that eating fiber can help reduce the risk. To 'fibermaxx,' they're eating more chia seeds in their yogurt bowls, making meals with more beans, and taking supplements. While nutritionists are largely supportive of the trend, they have a few caveats. 'More isn't always better,' Mascha Davis, a registered dietician nutritionist and the owner of Nomadista Nutrition, told Health this week. 'Many people don't get enough fiber, but it's just important to be thoughtful about how you're doing it so that it's not too much too fast,' Kate Mintz, a registered dietitian at U.C.L.A. Health, also recently told The New York Times. Fiber is often used to fight constipation, helping stools to pass easier. 'Even if you suffer from constipation, increasing fiber all at once could make the situation worse before you get cleared out,' Jennifer House, a dietitian and founder of First Step Nutrition, also explained to Health. Getting too much fiber could lead to a bloated and uncomfortable experience, according to the Mayo Clinic. People need to be careful and methodical, and talking to a physician can help to determine what's a right amount, on a case by case basis. What's more, when people with autoimmune conditions such as Crohn's disease see symptoms flare up, they may need to eat less fiber to help manage symptoms. After stomach or intestinal surgery, doctors may also instruct you to keep a lower fiber diet that lets your digestive system heal. Before a colonoscopy the advice may be similar, helping to clear out the large intestine to ensure a successful procedure. But in general, Americans aren't getting enough fiber - more than 90 percent of women and 97 percent of men do not meet the recommended daily intakes. Total dietary fiber intake should be 25 to 30 grams a day from food, and not supplements, according to UCSF Health. Currently, dietary fiber intakes among American adults average about only 15 grams a day. Fiber is good for your gut, heart, and brain, and may also slash the risk of type 2 diabetes and heart disease. The Mayo Clinic recommends adding fiber to the diet slowly over a few weeks, letting the natural bacteria in your digestive system adjust to the change. Staying hydrated is also crucial and fiber works best when it absorbs water. So, what can you eat to fiber to the max? The next time you're at the grocery store, pick up some popcorn, beans, cereal, apples, oranges, peas, cauliflower, or carrots. Raspberries are a particularly fiber-rich fruit, packed with eight grams. "If you're going to have a cookie, have an oatmeal cookie," Joanne Slavin, a professor of food science and nutrition at the University of Minnesota, told the American Heart Association. "It doesn't take large amounts of fiber to have a real effect.'
